Clinical-stage biotechnology company developing genetic medicines and gene therapies for musculoskeletal diseases
Clinical-stage biotechnology company developing genetic medicines and gene therapies for musculoskeletal diseases. Its lead program, GNSC-001, is an investigational gene therapy for knee osteoarthritis designed to produce interleukin-1 receptor antagonist (IL-1Ra) in the joint, inhibiting IL-1-driven inflammation and potentially reducing pain and cartilage damage.